Commissioning responsibility for ILD medicines

Roedd y cais yn rhannol lwyddiannus.

Dear NHS England,

Please can you confirm whether NHS England or CCGs are the responsible commissioner for the following oral medicines when used to treat Interstitial Lung Disease in England:

1) azathioprine
2) leflunomide
3) Methotrexate
4) mycophenolate mofetil

Yours faithfully,

Mark Hewert

FOITEAMCRMMAILBOX (NHS ENGLAND & NHS IMPROVEMENT - X24), NHS England

Dear  Mark Hewert ,

Thank you for your communication dated 21 February 2020.

NHS England has assessed your communication as a request under the Freedom
of Information (FOI) Act 2000. As such, please be assured that your
request is being dealt with under the terms of the FOI Act and will be
answered within twenty working days.

For further information regarding the FOI Act, please refer to the
Information Commissioner’s Office (ICO) website. For further information
regarding NHS England and the information it publishes please visit our
website here.

If you have any queries about this request or wish to contact us again,
please email [1][NHS England request email] and the message will be
forwarded appropriately. Please remember to quote the above reference
number in any future communications.

Please do not reply to this email. This message has been sent from a
central mailbox. To communicate with NHS England regarding Freedom of
Information (FOI) requests, enquiries or complaints we ask these are sent
directly to NHS England’s customer contact centre. This is to ensure all
communications are progressed correctly. Their postal address, telephone
number and email details are as follows:- PO Box 16738, Redditch, B97 9PT;
0300 3 11 22 33, [2][NHS England request email].

Yours sincerely, 

Freedom of Information
Corporate Communications Team
Transformation and Corporate Operations Directorate
NHS England
PO Box 16738
REDDITCH
B97 9PT
Tel: 0300 311 22 33
Email: [3][NHS England request email]

‘High quality care for all, now and for future generations’

 

dangos adrannau a ddyfynnir

FOITEAMCRMMAILBOX (NHS ENGLAND & NHS IMPROVEMENT - X24), NHS England

Dear Mark Hewart,   

Re:     Freedom of Information request (Our Ref:  FOI - 2002-1146620)

Thank you for your Freedom of Information (FOI) request dated 21 February
2020.

Your exact request was:-

Commissioning responsibility for ILD medicines
Dear NHS England,
Please can you confirm whether NHS England or CCGs are the responsible
commissioner for the following oral medicines when used to treat
Interstitial Lung Disease in England:
1) azathioprine
2) leflunomide
3) Methotrexate
4) mycophenolate mofetil

NHS England holds some of this information.

Please can you confirm whether NHS England or CCGs are the responsible
commissioner for the following oral medicines when used to treat
Interstitial Lung Disease in England:
1) azathioprine
2) leflunomide
3) Methotrexate
4) mycophenolate mofetil

NHS England is the responsible commissioner for specialised respiratory
services. However the cost of these drugs are included within inpatient
and outpatient tariffs. Therefore local access is covered by the relevant
Trusts Drugs and Therapeutic Committee and if shared care with a GP is
proposed the Clinical Commissioning Groups area prescribing committee
would need to consider if GPs would be allowed to prescribe it.

NHS England’s national Clinical Reference Group for Specialised
Respiratory has confirmed the following:
1) azathioprine
3) Methotrexate
4) mycophenolate mofetil
These drugs are immuosuppressives and are routinely & commonly used in the
treatment of ILD patients as steroid sparing treatments. They require
blood monitoring for safety purposes. This starts with Respiratory team
beginning the drug then once stable GPs will often take on longer
monitoring via shared care protocols if in place. Common ILD diseases
treated with these drugs include: sarcoidosis, connective tissue ILD,
hypersensitivity pneumonitis, cryptogenic organising pneumonia, Idiopathic
non-specific interstitial pneumonia (iNSIP).
 
2) leflunomide
Leflunomide is a DMARD- (disease modifying anti rheumatic drug). It is
used mostly by rheumatologists to treat rheumatoid arthritis. However, it
can also be used to treat sarcoidosis where other therapies have failed.
Our expert advice is that a minority of respiratory specialists may have
considered using it. If a hospital clinician wanted to use it they would
need to discuss this with their Hospitals drugs and therapeutics committee
and it is noted needs blood safety monitoring like the other drugs above.
 
Further information may be held by NHS Hospital Trusts or by Clinical
Commissioning Groups (CCGs). Please find web links to Trusts and CCGs
below:

You can find Trust contact information on the NHS website at the following
web link:

[1]https://www.nhs.uk/servicedirectories/pa...

You can find CCG contact information on the NHS  website at the following
web link:

[2]http://www.nhs.uk/ServiceDirectories/Pag...

Copyright:- NHS England operates under the terms of the open government
licence. Please see the NHS England Terms and conditions on the following
link
 

* [3]http://www.england.nhs.uk/terms-and-cond...

We hope this information is helpful. However, if you are dissatisfied, you
have the right to ask for an internal review. This should be requested in
writing within two months of the date of this letter. Your correspondence
should be labelled “Internal Review” and should outline your concerns
and/or the area(s) you would like the review to consider. Internal Review
requests should be sent to:

NHS England
PO Box 16738
REDDITCH
B97 9PT

Email: [4][NHS England request email]

Please quote the reference number  FOI - 2002-1146620 in any future
communications.

If you are not content with the outcome of the internal review, you have
the right to apply directly to the Information Commissioner for a
decision. The Information Commissioner’s Office (ICO) can be contacted at:

The Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF

Telephone: 0303 123 1113
Email: [5][email address]  
Website: [6]www.ico.org.uk

Please note there is no charge for making an appeal.

Please be aware that in line with the Information Commissioner’s directive
on the disclosure of information under the FOI Act, your request will be
anonymised and published on our website as part of our disclosure log.

Please do not reply to this email. This message has been sent from a
central mailbox. To communicate with NHS England regarding Freedom of
Information (FOI) requests, enquiries or complaints we ask these are sent
directly to NHS England’s customer contact centre. This is to ensure all
communications are progressed correctly. Their postal address, telephone
number and email details are as follows:- PO Box 16738, Redditch, B97 9PT;
0300 3 11 22 33, [7][NHS England request email].

Yours sincerely,

Freedom of Information
Corporate Communications Team
Transformation and Corporate Operations Directorate

NHS England
PO Box 16738
REDDITCH
B97 9PT

Tel: 0300 311 22 33
Email: [8][NHS England request email]

dangos adrannau a ddyfynnir